28.80
price down icon0.35%   -0.10
after-market アフターアワーズ: 29.19 0.39 +1.35%
loading
前日終値:
$28.90
開ける:
$28.12
24時間の取引高:
646.25K
Relative Volume:
0.56
時価総額:
$2.53B
収益:
$218.71M
当期純損益:
$-113.70M
株価収益率:
-22.10
EPS:
-1.3034
ネットキャッシュフロー:
$-73.47M
1週間 パフォーマンス:
-0.83%
1か月 パフォーマンス:
-12.03%
6か月 パフォーマンス:
-2.90%
1年 パフォーマンス:
+40.69%
1日の値動き範囲:
Value
$27.93
$29.18
1週間の範囲:
Value
$27.89
$29.39
52週間の値動き範囲:
Value
$16.82
$39.28

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name
名前
Ideaya Biosciences Inc
Name
セクター
Healthcare (1106)
Name
電話
650-443-6209
Name
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
職員
145
Name
Twitter
Name
次回の収益日
2026-05-05
Name
最新のSEC提出書
Name
IDYA's Discussions on Twitter

Compare IDYA vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IDYA icon
IDYA
Ideaya Biosciences Inc
28.80 2.54B 218.71M -113.70M -73.47M -1.3034
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 109.34B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 74.35B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 50.44B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 39.78B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.02B 5.36B 287.73M 924.18M 2.5229

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-07 再開されました UBS Buy
2025-11-24 開始されました Truist Buy
2025-09-18 開始されました Guggenheim Buy
2025-09-04 開始されました Barclays Overweight
2025-09-04 開始されました Citizens JMP Mkt Outperform
2025-07-22 開始されました TD Cowen Buy
2025-07-10 再開されました Goldman Neutral
2025-06-26 開始されました Wells Fargo Overweight
2024-11-18 開始されました Stephens Overweight
2024-11-05 ダウングレード Leerink Partners Outperform → Market Perform
2024-10-24 開始されました UBS Buy
2024-10-15 開始されました Cantor Fitzgerald Overweight
2024-07-08 開始されました Mizuho Outperform
2024-03-08 開始されました BTIG Research Buy
2023-08-08 開始されました SVB Securities Outperform
2023-05-24 開始されました Goldman Buy
2023-04-24 アップグレード Stifel Hold → Buy
2023-03-23 開始されました Berenberg Buy
2023-02-28 開始されました RBC Capital Mkts Outperform
2022-12-28 開始されました CapitalOne Overweight
2022-10-27 開始されました Citigroup Buy
2022-08-15 ダウングレード Stifel Buy → Hold
2022-07-18 再開されました Oppenheimer Outperform
2022-03-10 アップグレード Stifel Hold → Buy
2021-09-23 開始されました Stifel Hold
2021-06-04 再開されました Robert W. Baird Outperform
2021-03-11 開始されました Guggenheim Buy
2020-10-07 開始されました Wedbush Outperform
2020-09-01 開始されました Northland Capital Outperform
2020-07-13 アップグレード JP Morgan Neutral → Overweight
2020-06-17 繰り返されました H.C. Wainwright Buy
2020-04-06 開始されました H.C. Wainwright Buy
2020-03-13 開始されました ROTH Capital Buy
2019-10-17 開始されました Oppenheimer Outperform
2019-09-10 開始されました Robert W. Baird Outperform
2019-06-17 開始されました Citigroup Buy
2019-06-17 開始されました JP Morgan Neutral
2019-06-17 開始されました Jefferies Buy
すべてを表示

Ideaya Biosciences Inc (IDYA) 最新ニュース

pulisher
May 05, 2026

IDEAYA Biosciences Files New Shelf Registration Statement - TipRanks

May 05, 2026
pulisher
May 05, 2026

IDEAYA Biosciences, Inc. Files Form 8-K SEC Report for May 5, 2026 – Company Information and Common Stock Details - Minichart

May 05, 2026
pulisher
May 05, 2026

IDEAYA (NASDAQ: IDYA) renews shelf, keeps $156.6M ATM capacity - Stock Titan

May 05, 2026
pulisher
May 05, 2026

IDEAYA (NASDAQ: IDYA) has $156.55M ATM capacity remaining under Jefferies sales pact - Stock Titan

May 05, 2026
pulisher
May 05, 2026

IDEAYA (NASDAQ: IDYA) files shelf to sell common stock, debt and warrants - Stock Titan

May 05, 2026
pulisher
May 05, 2026

IDEAYA (NASDAQ: IDYA) reports Q1 loss but holds $972.9M cash - Stock Titan

May 05, 2026
pulisher
May 05, 2026

IDEAYA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 05, 2026
pulisher
May 05, 2026

IDEAYA Biosciences 1Q Loss $98.5M >IDYA - Moomoo

May 05, 2026
pulisher
May 05, 2026

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance Singapore

May 05, 2026
pulisher
May 05, 2026

IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace

May 05, 2026
pulisher
May 05, 2026

Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, vs. FactSet Est of $5.0M - marketscreener.com

May 05, 2026
pulisher
May 05, 2026

Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, Vs. FactSet Est of $5.0M - Moomoo

May 05, 2026
pulisher
May 05, 2026

IDEAYA (IDYA) posts Q1 2026 loss, advances darovasertib NDA plan - Stock Titan

May 05, 2026
pulisher
May 05, 2026

IDEAYA says eye cancer drug combo cut progression risk 58% - Stock Titan

May 05, 2026
pulisher
May 05, 2026

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow

May 05, 2026
pulisher
May 03, 2026

Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Insider Monkey

May 03, 2026
pulisher
May 02, 2026

Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily

May 02, 2026
pulisher
May 01, 2026

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Pictet Asset Management Holding SA - MarketBeat

May 01, 2026
pulisher
May 01, 2026

Five new IDEAYA hires receive stock options at $29.10 a share - Stock Titan

May 01, 2026
pulisher
Apr 30, 2026

LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - BioSpace

Apr 30, 2026
pulisher
Apr 30, 2026

IDEAYA to file NDA for uveal melanoma drug under FDA fast review - Investing.com Canada

Apr 30, 2026
pulisher
Apr 29, 2026

Executive pay and auditor vote headline IDEAYA (NASDAQ: IDYA) 2026 meeting - Stock Titan

Apr 29, 2026
pulisher
Apr 27, 2026

Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

RBC Capital Maintains IDEAYA Biosciences (IDYA) Outperform Recommendation - MSN

Apr 27, 2026
pulisher
Apr 24, 2026

IDEAYA Biosciences Advances Precision Oncology with AI Discovery - HarianBasis.co

Apr 24, 2026
pulisher
Apr 24, 2026

IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout - Insider Monkey

Apr 24, 2026
pulisher
Apr 23, 2026

IDYA (IDEAYA Biosciences Inc.) posts narrower than expected Q4 2025 loss, shares rise 4.31 percent.Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026
pulisher
Apr 22, 2026

IDYA (IDEAYA Biosciences Inc.) reports narrower Q4 2025 loss than projections, but stock dips slightly in today's trading.Pro Level Trade Signals - Xã Thanh Hà

Apr 22, 2026
pulisher
Apr 22, 2026

IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application - MSN

Apr 22, 2026
pulisher
Apr 21, 2026

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Mel - BioSpace

Apr 21, 2026
pulisher
Apr 21, 2026

IDEAYA And AstraZeneca Collaboration Adds New Dimension To IDE849 And Valuation - simplywall.st

Apr 21, 2026
pulisher
Apr 21, 2026

IDEAYA to present trial data at ASCO meeting in June By Investing.com - Investing.com Australia

Apr 21, 2026
pulisher
Apr 21, 2026

IDEAYA to present trial data at ASCO meeting in June - Investing.com

Apr 21, 2026
pulisher
Apr 21, 2026

Trading the Move, Not the Narrative: (IDYA) Edition - Stock Traders Daily

Apr 21, 2026
pulisher
Apr 21, 2026

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 4.5%Here's Why - MarketBeat

Apr 21, 2026
pulisher
Apr 21, 2026

Why IDEAYA Biosciences Stock Is Suddenly Sinking - TipRanks

Apr 21, 2026
pulisher
Apr 21, 2026

IDEAYA gets late-breaking ASCO slot for full uveal melanoma data - Stock Titan

Apr 21, 2026
pulisher
Apr 18, 2026

Is IDEAYA Biosciences (IDYA) stock risky for investors (Builds on Momentum) 2026-04-18AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026
pulisher
Apr 18, 2026

IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Apr 18, 2026
pulisher
Apr 14, 2026

IDEAYA Biosciences Inc : JP Morgan Raises Tar - Moomoo

Apr 14, 2026
pulisher
Apr 14, 2026

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 3.5%Should You Sell? - MarketBeat

Apr 14, 2026
pulisher
Apr 14, 2026

Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says - marketscreener.com

Apr 14, 2026
pulisher
Apr 14, 2026

IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat

Apr 14, 2026
pulisher
Apr 14, 2026

Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals

Apr 14, 2026
pulisher
Apr 14, 2026

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars - Sahm

Apr 14, 2026
pulisher
Apr 14, 2026

Guggenheim raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada

Apr 14, 2026
pulisher
Apr 14, 2026

RBC Capital raises Ideaya Biosciences stock price target on trial data - Investing.com Canada

Apr 14, 2026
pulisher
Apr 14, 2026

Tudor Investment Corp ET AL Purchases New Position in IDEAYA Biosciences, Inc. $IDYA - MarketBeat

Apr 14, 2026
pulisher
Apr 14, 2026

Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance

Apr 14, 2026
pulisher
Apr 14, 2026

Wedbush Forecasts Strong Price Appreciation for IDEAYA Biosciences (NASDAQ:IDYA) Stock - MarketBeat

Apr 14, 2026

Ideaya Biosciences Inc (IDYA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):